Intetumumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade from ProteoGenix; catalogue PX-TA1230; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Intetumumab Biosimilar is a monoclonal antibody (mAb) that targets the integrin alpha V beta 3 (ITGAV_ITGB3) receptor. It is a research grade antibody that has shown promising results in pre-clinical studies and is being developed as a potential therapeutic agent for various diseases.
Intetumumab Biosimilar is a humanized IgG1 monoclonal antibody with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region of the antibody is responsible for its specificity towards the ITGAV_ITGB3 receptor.
The main activity of Intetumumab Biosimilar is to bind to the ITGAV_ITGB3 receptor, which is a cell surface receptor that plays a crucial role in cell adhesion, migration, and proliferation. This receptor is overexpressed in various types of cancer cells, making it an attractive therapeutic target. By binding to the ITGAV_ITGB3 receptor, Intetumumab Biosimilar blocks its activity and inhibits the growth and spread of cancer cells.
1.
Intetumumab Biosimilar has shown promising results in pre-clinical studies as a potential treatment for various types of cancer. It has been shown to inhibit the growth and spread of cancer cells by targeting the ITGAV_ITGB3 receptor. This makes it a potential therapeutic option for cancers such as melanoma, breast cancer, and prostate cancer.
2. Angiogenesis inhibition:
Intetumumab Biosimilar has also been studied for its ability to inhibit angiogenesis, which is the formation of new blood vessels. Angiogenesis plays a crucial role in the growth and spread of cancer, and by targeting the ITGAV_ITGB3 receptor, Intetumumab Biosimilar can potentially inhibit this process.
3. Rheumatoid arthritis:
The ITGAV_ITGB3 receptor has been implicated in the development of rheumatoid arthritis, a chronic inflammatory disease that affects the joints. By targeting this receptor, Intetumumab Biosimilar has shown potential in reducing inflammation and joint damage in pre-clinical studies.
4. Osteoporosis:
Intetumumab Biosimilar has also been studied for its potential in treating osteoporosis, a condition characterized by weak and brittle bones. The ITGAV_ITGB3 receptor has been found to play a role in bone remodeling, and by targeting it, Intetumumab Biosimilar can potentially improve bone density and strength.
5. Other diseases:
Apart from the above-mentioned applications, Intetumumab Biosimilar is also being studied for its potential in other diseases such as psoriasis, atherosclerosis, and diabetic retinopathy. The ITGAV_ITGB3 receptor has been found to play a role in the pathogenesis of these diseases, and by targeting it, Intetumumab Biosimilar can potentially provide therapeutic benefits.
Intetumumab Biosimilar is a promising research grade antibody that targets the ITGAV_ITGB3 receptor. Its ability to inhibit the growth and spread of cancer cells and its potential in treating other diseases make it a valuable therapeutic option. Further clinical studies are needed to fully understand the potential of Intetumumab Biosimilar and its role in the treatment of various diseases.
ProteoGenix catalogue number PX-TA1230. For research use only.
Target: Intetumumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Intetumumab Biosimilar – Anti-ITGAV_ITGB3 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
